Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 16;9(20):5442-5452.
doi: 10.12998/wjcc.v9.i20.5442.

Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review

Affiliations

Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review

Jian-Xia Xiong et al. World J Clin Cases. .

Abstract

Background: Dermatofibrosarcoma protuberans (DFSP) is a rare low-grade malignant soft tissue tumor characterized by rosette-like infiltrative growth. Postoperative recurrence of this tumor is very common.

Aim: To evaluate the risk factors related to recurrence after wide local excision (WLE) of DFSP and to guide clinical diagnosis and treatment.

Methods: The medical records of 44 DFSP patients confirmed by pathology at our hospital from 2012 to 2019 were retrospectively reviewed. The relationship between clinical features, tumor characteristics, treatment, and recurrence risk were analyzed, and the possible risk factors for postoperative tumor recurrence were evaluated.

Results: There were 44 patients in total, including 21 males and 23 females. The median progression free survival was 36 mo (range, 1-240 mo). Twenty patients were treated for the first time, while 24 had previous treatment experience. Forty-two cases were followed for 25.76 ± 22.0 mo, among whom four (9.52%) experienced recurrence after WLE (rate was 9.52%). The recurrence rate in the recurrent group was higher than that in the patients with primary tumor (19.05% vs 0%, P = 0.028). Eighteen cases had a history of misdiagnosis (rate was 40.91%). The recurrence rate among patients with previous experience of misdiagnosis was significantly higher than in patients without (68% vs 36.84%, P = 0.04). The tumor diameter in patients with a history of treatment was larger than in patients treated for the first time (4.75 ± 0.70 cm vs 2.25 ± 0.36 cm, P = 0.004).

Conclusion: To sum up, the clinical manifestations of DFSP are not specific and are easily misdiagnosed, thus commonly causing the recurrence of DFSP. After incomplete resection, the tumor may rapidly grow. Previous recurrence history may be a risk factor for postoperative recurrence, and tumor location may have an indirect effect on postoperative recurrence; however, we found no significant correlation between sex, age, course of the disease, or tumor size and postoperative recurrence.

Keywords: Clinical features; Dermatofibrosarcoma protuberans; Recurrence; Retrospective research; Surgery; Wide local excision.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that there is no conflict of interests regarding the publication of this paper.

Similar articles

Cited by

References

    1. Malkud S, Dyavannanavar V. Dermatofibrosarcoma Protuberans. Indian Dermatol Online J. 2017;8:495–497. doi: 10.4103/idoj.IDOJ_424_16. - DOI - PMC - PubMed
    1. Allen A, Ahn C, Sangüeza OP. Dermatofibrosarcoma Protuberans. Dermatol Clin. 2019;37:483–488. doi: 10.1016/j.det.2019.05.006. - DOI - PubMed
    1. Trofymenko O, Zeitouni NC. Association of patient demographic characteristics with dermatofibrosarcoma protuberans tumour size at diagnosis in the U.S. National Cancer Database. Br J Dermatol. 2017;177:e103–e104. doi: 10.1111/bjd.15357. - DOI - PubMed
    1. Reha J, Katz SC. Dermatofibrosarcoma Protuberans. Surg Clin North Am. 2016;96:1031–1046. doi: 10.1016/j.suc.2016.05.006. - DOI - PubMed
    1. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003;37:1–19. doi: 10.1002/gcc.10202. - DOI - PubMed